Prospects of Fecal Microbiota Transplantation for Inflammatory Bowel Disease in the Context of Biological Agents

Zhongshun NIE; Yinglei MIAO

doi:10.12259/j.issn.2095-610X.S20241023

Volume 45 Issue 10

Oct. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 > 45(10): 147-154

Zhongshun NIE, Yinglei MIAO. Prospects of Fecal Microbiota Transplantation for Inflammatory Bowel Disease in the Context of Biological Agents[J]. Journal of Kunming Medical University, 2024, 45(10): 147-154. doi: 10.12259/j.issn.2095-610X.S20241023

Citation:

Zhongshun NIE, Yinglei MIAO. Prospects of Fecal Microbiota Transplantation for Inflammatory Bowel Disease in the Context of Biological Agents[J]. Journal of Kunming Medical University, 2024, 45(10): 147-154. doi: 10.12259/j.issn.2095-610X.S20241023

Citation:

PDF( 598 KB)

Prospects of Fecal Microbiota Transplantation for Inflammatory Bowel Disease in the Context of Biological Agents

doi: 10.12259/j.issn.2095-610X.S20241023

Zhongshun NIE,
Yinglei MIAO^,

Dept. of Gastroenterology，The 1st Affilited Hospital of Kunming Medical University，Kunming Yunnan 650032，China

Received Date: 2024-06-11
Available Online: 2024-10-12
Publish Date: 2024-10-31

Abstract

Abstract

Inflammatory bowel disease （IBD） is a chronic, non-specific inflammatory condition of the intestines, and its mechanisms are still unclear, with effective treatments lacking. The advent of biologics has opened a new chapter in the treatment of IBD, with some patients achieving clinical remission or even mucosal healing. However, in clinical practice, there are still quite a few patients who either do not respond to initial treatment or experience secondary loss of response, making it difficult to fully control disease progression. Research shows that changes in the gut microbiota play a crucial role in the onset and progression of IBD, and they may serve as predictive factors for assessing the efficacy of biologics. Fecal microbiota transplantation （FMT）, as a new treatment method to restore the gut microecology of patients, has shown some effectiveness in improving IBD symptoms, inducing and maintaining mucosal healing, and even achieving histological remission. What does the future hold for the application of FMT in IBD patients in the era of biologics? This review will summarize relevant research results from both domestic and international sources to provide a theoretical basis for the potential and feasibility of using FMT in treating IBD during the biologics era.
- Inflammatory bowel disease,
- Fecal microbiota transplantation,
- Biologics,
- Gut microbiota

FullText(HTML)

References(66)

References

[1]	Fabian O K. Kamaradova,Morphology of inflammatory bowel diseases (IBD)[J]. Cesk Patol,2022,58(1):27-37.
[2]	Vancamelbeke M. Genetic and Transcriptomic bases of intestinal epithelial barrier dysfunction in inflammatory Bowel Disease[J]. Inflamm Bowel Dis,2017,23(10):1718-1729. doi: 10.1097/MIB.0000000000001246
[3]	Burmester G R. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis,juvenile idiopathic arthritis,ankylosing spondylitis,psoriatic arthritis,psoriasis and Crohn's disease[J]. Ann Rheum Dis,2013,72(4):517-524. doi: 10.1136/annrheumdis-2011-201244
[4]	Sandborn W J. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial[J]. Gut,2007,56(9):1232-1239. doi: 10.1136/gut.2006.106781
[5]	Ventin-Holmberg R. Bacterial and fungal profiles as markers of infliximab drug response in inflammatory bowel disease[J]. J Crohns Colitis,2021,15(6):1019-1031. doi: 10.1093/ecco-jcc/jjaa252
[6]	Cui B. Step-up fecal microbiota transplantation (FMT) strategy[J]. Gut Microbes,2016,7(4):323-328. doi: 10.1080/19490976.2016.1151608
[7]	Liu J,Di B ,XU L L. Recent advances in the treatment of IBD: Targets,mechanisms and related therapies[J]. Cytokine Growth Factor Rev,2023, 71: 1-12.
[8]	Baumgart D C,Le Berre C. Newer biologic and small-molecule therapies for inflammatory bowel disease[J]. N Engl J Med,2021,385(14): 1302-1315.
[9]	Greuter T. Emerging treatment options for extraintestinal manifestations in IBD[J]. Gut,2021,70(4):796-802. doi: 10.1136/gutjnl-2020-322129
[10]	Brandse J F. Serum concentration of anti-TNF antibodies,adverse effects and quality of life in patients with inflammatory bowel disease in remission on maintenance treatment[J]. J Crohns Colitis,2015,9(11):973-981. doi: 10.1093/ecco-jcc/jjv116
[11]	Mercer L K,et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers[J]. Ann Rheum Dis,2017. 76(2): 386-391.
[12]	Vermeirem S. Immunogenicity of biologics in inflammatory bowel disease[J]. Therap Adv Gastroenterol,2018,11: 1756283X17750355.
[13]	Ben-Horin S,U. Kopylov,Y. Chowers. Optimizing anti-TNF treatments in inflammatory bowel disease[J]. Autoimmun Rev,2014,13(1):24-30. doi: 10.1016/j.autrev.2013.06.002
[14]	Kennedy N A. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: A prospective,multicentre,cohort study[J]. Lancet Gastroenterol Hepatol,2019. 4(5): 341 -353.
[15]	Zhang S. Comparison between washed microbiota transplantation and infliximab: Medical cost during long-term management in patients with inflammatory bowel disease[J]. J Chin Med Assoc,2024,87(1):109-118.
[16]	Hassouneh R. ,Bajaj J S,Gut microbiota modulation and fecal transplantation: An overview on innovative strategies for hepatic encephalopathy treatment[J]. J Clin Med,2021,10(2):330. doi: 10.3390/jcm10020330
[17]	Eiseman B. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis[J]. Surgery,1958,44(5):854-859.
[18]	Ancona A. The gut-brain axis in irritable bowel syndrome and inflammatory bowel disease[J]. Dig Liver Dis,2021,53(3):298-305. doi: 10.1016/j.dld.2020.11.026
[19]	Goeser F. Fecal microbiota transfer for refractory intestinal graft-versus-host disease-experience from two german tertiary centers[J]. Eur J Haematol,2021,107(2):229-245. doi: 10.1111/ejh.13642
[20]	Smillie C S. Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation[J]. Cell Host Microbe,2018,23(2): 229-240. e5.
[21]	Zhang W. Fecal microbiota transplantation (FMT) alleviates experimental colitis in mice by gut microbiota regulation[J]. J Microbiol Biotechnol,2020,30(8):1132-1141. doi: 10.4014/jmb.2002.02044
[22]	Paramsothy S. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: A randomised placebo-controlled trial[J]. Lancet,2017,389(10075):1218-1228. doi: 10.1016/S0140-6736(17)30182-4
[23]	Haifer C. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): A randomised,double-blind,placebo-controlled trial[J]. Lancet Gastroenterol Hepatol,2022,7(2):141-151. doi: 10.1016/S2468-1253(21)00400-3
[24]	Paramsothy S. Faecal microbiota transplantation for Inflammatory bowel disease: A systematic review and meta-analysis[J]. J Crohns Colitis,2017,11(10):1180-1199. doi: 10.1093/ecco-jcc/jjx063
[25]	Sokol H. Fmicrobiota transplantation to maintain remission in Crohn's disease: A pilot randomized controlled study[J]. Microbiome,2020,8(1): 12.
[26]	Schierova D. Gut microbiome changes in patients with active left-sided ulcerative colitis after fecal microbiome transplantation and topical 5-aminosalicylic acid therapy[J]. Cells,2020,9(10):2283. doi: 10.3390/cells9102283
[27]	Zhang F M. Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn's disease[J]. World J Gastroenterol,2013,19(41):7213-7216. doi: 10.3748/wjg.v19.i41.7213
[28]	Vandenplas. Fecal microbial transplantation in early-onset colitis: caution advised[J]. J Pediatr Gastroenterol Nutr,2015,61(3):e12-14.
[29]	Shimizu H. Repeated fecal microbiota transplantation in a child with ulcerative colitis[J]. Pediatr Int,2016,58(8):781-785. doi: 10.1111/ped.12967
[30]	Wang Y. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis[J]. Nat Med,2018,24(12):1804-1808. doi: 10.1038/s41591-018-0238-9
[31]	Uygun A. Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis[J]. Medicine (Baltimore),2017,96(16):e6479.
[32]	Narula N. Systematic Review and meta-analysis: Fecal microbiota transplantation for treatment of active ulcerative colitis[J]. Inflamm Bowel Dis,2017,23(10):1702-1709. doi: 10.1097/MIB.0000000000001228
[33]	He Z. Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn's disease complicated with inflammatory mass[J]. Sci Rep,2017,7(1):4753. doi: 10.1038/s41598-017-04984-z
[34]	mmXiang L. Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment? [J]Microb Biotechnol,2020,13(3): 760-769.
[35]	Costello S P. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: A randomized clinical trial[J]. JAMA,2019,321(2):156-164. doi: 10.1001/jama.2018.20046
[36]	Wu X. The Underlying Changes in serum metabolic profiles and efficacy prediction in patients with extensive ulcerative colitis undergoing fecal microbiota transplantation[J]. Nutrients,2023,15(15):3340. doi: 10.3390/nu15153340
[37]	Cui B. Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety,feasibility,and efficacy trial results[J]. J Gastroenterol Hepatol,2015,30(1):51-58. doi: 10.1111/jgh.12727
[38]	Cui B. Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative coliti[J]. J Transl Med,2015,13:298.
[39]	杨艳. 溃疡性结肠炎患者对粪菌移植的认知及接受度研究[J]. 河南医学研究,2023,32(3):411-416. doi: 10.3969/j.issn.1004-437X.2023.03.006
[40]	Marshall D A. Patient preferences for active ulcerative colitis treatments and fecal microbiota transplantation[J]. Ther Adv Chronic Dis,2024,15: 20406223241239168.
[41]	Shin J. Complementary therapeutic effect of fecal microbiota transplantation in ulcerative colitis after the response to anti-tumor necrosis factor alpha agent was lost: A case report[J]. Biomedicines,2024,12(4):800. doi: 10.3390/biomedicines12040800
[42]	Hsu M. Safety and efficacy of fecal microbiota transplantation in treatment of inflammatory bowel disease in the pediatric population: A systematic review and meta-analysis[J]. Microorganisms,2023,11(5):1272. doi: 10.3390/microorganisms11051272
[43]	Fang H,Fu L ,Wang J. Protocol for fecal microbiota transplantation in inflammatory bowel disease: A systematic review and meta-analysis[J]. Biomed Res Int,2018,2018: 8941340.
[44]	Popov J. Pediatric patient and parent perceptions of fecal microbiota transplantation for the treatment of ulcerative colitis[J]. J Pediatr Gastroenterol Nutr,2021,73(6):684-688. doi: 10.1097/MPG.0000000000002995
[45]	Magnusson M K. Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition[J]. Journal of Crohn's and Colitis,2016,10(8):943-952. doi: 10.1093/ecco-jcc/jjw051
[46]	Aden K. Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel diseases[J]. Gastroenterology,2019,157(5): 1279-1292. e11.
[47]	Yilmaz B. Publisher correction: Microbial network disturbances in relapsing refractory Crohn's disease[J]. Nat Med,2019,25(4):701.
[48]	Wang Y. Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn's disease[J]. Gut Microbes,2021,13(1):1-18.
[49]	Radhakrishnan S T. Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease[J]. Aliment Pharmacol Ther,2022,55(1):26-48. doi: 10.1111/apt.16656
[50]	Jiang L. A metabolomics-driven model for early remission prediction following vedolizumab treatment in patients with moderate-to-severe active ulcerative colitis[J]. Int Immunopharmacol,2024,128:111527. doi: 10.1016/j.intimp.2024.111527
[51]	Zhang F. Microbiota transplantation: concept,methodology and strategy for its modernization[J]. Protein Cell,2018,9(5):462-473. doi: 10.1007/s13238-018-0541-8
[52]	Wang H. The safety of fecal microbiota transplantation for crohn's disease: Findings from a long-term study[J]. Adv Ther,2018,35(11):1935-1944. doi: 10.1007/s12325-018-0800-3
[53]	Li P. Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn's disease[J]. Appl Microbiol Biotechnol,2019,103(1):349-360. doi: 10.1007/s00253-018-9447-x
[54]	Tkach S. Efficacy and safety of fecal microbiota transplantation via colonoscopy as add-on therapy in patients with mild-to-moderate ulcerative colitis: A randomized clinical trial[J]. Front Med (Lausanne),2022,9:1049849.
[55]	Sakai K. Intestinal microbiota and gene expression reveal similarity and dissimilarity between immune-mediated colitis and ulcerative colitis[J]. Front Oncol,2021,11:763468. doi: 10.3389/fonc.2021.763468
[56]	HalseyT M. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis[J]. Sci Transl Med,2023,15(7):eabq4006. doi: 10.1126/scitranslmed.abq4006
[57]	Nicholson M R. Efficacy and Outcomes of Faecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease[J]. J Crohns Colitis,2022,16(5):768-777. doi: 10.1093/ecco-jcc/jjab202
[58]	Agrawal M,et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent,severe,and complicated clostridium difficile infection in 146 elderly individuals[J]. J Clin Gastroenterol,2016,50(5): 403-407.
[59]	Saeedi B J. Fecal microbiota transplant for clostridium difficile infection in a pregnant patient[J]. Obstet Gynecol,2017,129(3):507-509. doi: 10.1097/AOG.0000000000001911
[60]	Wright E K,Ding N S,Niewiadomski O,Management of inflammatory bowel disease[J]. Med J Aust,2018,209(7): 318-323.
[61]	Carlson P J. Regulatory considerations for fecal microbiota transplantation products[J]. Cell Host Microbe,2020,27(2):173-175. doi: 10.1016/j.chom.2020.01.018
[62]	Porcari S,et al. Fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with concurrent ulcerative colitis[J]. J Autoimmun,2023. 141: 103033.
[63]	van Lingen E E. Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent Clostridioides difficile infection in patients with inflammatory bowel disease[J]. Therap Adv Gastroenterol,2023,16: 17562848231156285.
[64]	Lopetuso L R,et al. The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease[J]. Gut,2023. 72(9): 1642-1650.
[65]	Gordon H. ECCO guidelines on Inflammatory Bowel Disease and Malignancies[J]. J Crohns Colitis,2023,17(6):827-854. doi: 10.1093/ecco-jcc/jjac187
[66]	Nanjing consensus on methodology of washed microbiota transplantation[J]. Chin Med J (Engl),2020,133(19): 2330-2332.

Relative Articles(20)

Relative Articles

[1]	Hanyu ZHANG, Juan LUO, Mingzhi DONG, Qiyin CHEN, Fengrui ZHANG, Rui GUO, Junying TONG, Yinglei MIAO. Retrospective Cohort Study of Infliximab and Vederizumab in the Treatment of Moderate-to-severe Ulcerative Colitis. Journal of Kunming Medical University, 2025, 46(4): 1-9.
[2]	Hanyu ZHANG, Juan LUO, Mingzhi DONG, Qiyin CHEN, Fengrui ZHANG, Rui GUO, Junying TONG, Yinglei MIAO. Retrospective Cohort Study of Infliximab and Vederizumab in the Treatment of Moderate-to-severe Ulcerative Colitis. Journal of Kunming Medical University, 2024, 45(10): 36-44. doi: 10.12259/j.issn.2095-610X.S20241006
[3]	Junjie NIU, Wenjuan JI, Zhuaizhuai YU. Correlation between Gut Microbiota，Serum ET，PCT Levels with the Severity and Prognosis of Sepsis. Journal of Kunming Medical University, 2024, 45(4): 140-145. doi: 10.12259/j.issn.2095-610X.S20240420
[4]	Yuanyuan LI, Yaxian SONG, Yushan XU, Xiaofu ZENG, Hui YUAN, Zhao XU, Yan JIANG. The Association of Intestinal Flora Metabolite TMAO with Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2024, 45(2): 77-84. doi: 10.12259/j.issn.2095-610X.S20240210
[5]	Bo LI, Yang SUN, Yinglei MIAO. Intestinal Microecological Changes and Therapeutics in Inflammatory Bowel Disease. Journal of Kunming Medical University, 2024, 45(4): 1-8. doi: 10.12259/j.issn.2095-610X.S20240401
[6]	Zhangqin LI, Qi HUANG, Yinglei MIAO. Research Progress on Paradoxical Extraintestinal Manifestations of Biologics in the Treatment of Inflammatory Bowel Disease. Journal of Kunming Medical University, 2024, 45(2): 160-165. doi: 10.12259/j.issn.2095-610X.S20240223
[7]	Lin XU, Kaicheng GAO, Jie JIA, Yuyang LI, Huawei WANG, Yiqun KUANG, Yu ZHAO. Effect of Shen-ling-bai-zhu-san on Methamphetamine-Induced Gut Microbiota Change in Mice. Journal of Kunming Medical University, 2023, 44(8): 37-43. doi: 10.12259/j.issn.2095-610X.S20230829
[8]	Shaoyou DENG, Yulan ZHAO, Peijin WANG, Rong LI, Jintao LI, Hong ZHENG. Effects of Osteoking Combined with Antibiotic Cocktail on Insulin Resistance and Gut Flora in db/db Mice. Journal of Kunming Medical University, 2023, 44(5): 12-18. doi: 10.12259/j.issn.2095-610X.S20230530
[9]	Caihong LIANG, Mingyao MENG, Xinxin LI, Jingjing XIONG, Meng LI, Mei LIU, Zongliu HOU, Yongkun HUANG. Effect of Intestinal Flora Metabolites Deoxycholic Acid on the Proliferation and Cell Cycle of Human Umbilical Cord Mesenchymal Stem Cells. Journal of Kunming Medical University, 2023, 44(4): 23-30. doi: 10.12259/j.issn.2095-610X.S20230402
[10]	Dan LI, Xulian WAN, Lvyu LI, Yu YUN, Guangyun LUO, Weibing LIU, Gongfu LIN, Ning LI, Yongkun LI, Weigang DUAN. Intestinal Flora in Uricase-Deficient Rats. Journal of Kunming Medical University, 2023, 44(2): 27-32. doi: 10.12259/j.issn.2095-610X.S20230205
[11]	Lu LI, Yunfen TIAN. Research Progress on Intestinal Microflora and Non-alcoholic Fatty Liver Disease in Children. Journal of Kunming Medical University, 2023, 44(7): 148-155. doi: 10.12259/j.issn.2095-610X.S20230708
[12]	Shunhang YANG, Jiongming LI, Jianhe LIU, Guang WANG, Pei LI. Progress in Pathogenesis and Treatment of Enteric Hyperoxaluria. Journal of Kunming Medical University, 2022, 43(7): 152-155. doi: 10.12259/j.issn.2095-610X.S20220734
[13]	Yanqin RUAN, Maojuan LI, Limei HE, Ying SONG, Qiaoyun HUANG, Ying CHEN, Chang LIU. Screening of Special Abnormal Module Items in PRO Scale for Patients with Inflammatory Bowel Disease.. Journal of Kunming Medical University, 2022, 43(3): 37-43. doi: 10.12259/j.issn.2095-610X.S20220310
[14]	Rong LIU, Yang SUN, Fameng LUO, Dezhi TAO, Haiyan ZHANG. Correlation between the Acceptance of Illness and Quality of Life in Patients with Inflammatory Bowel Disease. Journal of Kunming Medical University, 2022, 43(5): 173-178. doi: 10.12259/j.issn.2095-610X.S20220507
[15]	Sixiang LIU, Yongkun HUANG, Mingying WANG, Hongwei HU, Min MA, Yu LING. Analysis of Intestinal Flora and Therapeutic Intervention in Children with Functional Constipation. Journal of Kunming Medical University, 2022, 43(3): 123-127. doi: 10.12259/j.issn.2095-610X.S20220309
[16]	Xiaolin LIU, Xiaocui CHEN, Yang SUN, Minli LI, Yinglei MIAO. Clinical Efficacy and Safety Evaluation of Fecal Bacteria Transplantation by Different Ways on Ulcerative Colitis. Journal of Kunming Medical University, 2022, 43(6): 46-51. doi: 10.12259/j.issn.2095-610X.S20220612
[17]	Liang Rui , Chun Yu Wei Xun , Shen Dao , Sun Le , Li Yun Feng . . Journal of Kunming Medical University, 2020, 41(06): 156-161.
[18]	Ping-yan XUE, Yan JIANG, Yu-shan XU, Hui YUAN, Xuan LI, Ya-xian SONG, Hua LIU. Changes of Intestinal Flora in Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2020, 41(11): 62-67. doi: 10.12259/j.issn.2095-610X.S20201120
[19]	Wang Rui Tao , Jia Qing An , Mou Yi Ping , Geng Zhi Min , Liu Chang . The Clinical Evaluation of Danning Tablets on Regulating Gut Flora Displacement to Eliminate Biliary Inflammation and Prevent Gallstone Formation. Journal of Kunming Medical University, 2018, 39(01): 109-112.
[20]	Zhang An Xing , Wu Jing , Sun Yang , Miao Ying Lei . . Journal of Kunming Medical University, 2018, 39(09): 128-132.